Shares of Renovaro Inc. (NASDAQ:RENB - Get Free Report) shot up 0.1% during trading on Tuesday . The company traded as high as $0.32 and last traded at $0.31. 961,250 shares changed hands during trading, a decline of 40% from the average session volume of 1,611,336 shares. The stock had previously closed at $0.31.
Renovaro Stock Performance
The firm has a market cap of $53.17 million, a P/E ratio of -0.40 and a beta of 0.51. The stock's 50 day simple moving average is $0.32 and its 200 day simple moving average is $0.52.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in RENB. ProShare Advisors LLC purchased a new position in Renovaro during the fourth quarter worth about $27,000. Voya Investment Management LLC purchased a new position in Renovaro during the fourth quarter worth about $30,000. The Manufacturers Life Insurance Company purchased a new position in Renovaro during the fourth quarter worth about $38,000. Price T Rowe Associates Inc. MD boosted its holdings in Renovaro by 183.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 45,198 shares of the company's stock worth $38,000 after purchasing an additional 29,253 shares during the last quarter. Finally, Corebridge Financial Inc. boosted its holdings in Renovaro by 114.8% during the fourth quarter. Corebridge Financial Inc. now owns 57,495 shares of the company's stock worth $48,000 after purchasing an additional 30,727 shares during the last quarter. 71.41% of the stock is currently owned by hedge funds and other institutional investors.
Renovaro Company Profile
(
Get Free Report)
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
Featured Articles
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access